According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the topic of several other reports. ValuEngine downgraded shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a report on Saturday, December 21st. Stifel Nicolaus raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating and increased their price objective for the company from $10.00 to $18.00 in a research report on Wednesday, January 8th. BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a buy rating to a strong-buy rating in a research note on Friday, January 3rd. Citigroup started coverage on shares of DBV TECHNOLOGIE/S in a report on Monday, December 16th. They set a buy rating and a $14.00 target price for the company. Finally, Oddo Bhf upgraded shares of DBV TECHNOLOGIE/S from a neutral rating to a buy rating in a research note on Wednesday, October 16th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $17.00.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its position in shares of DBV TECHNOLOGIE/S by 10.2% in the second quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock worth $109,000 after purchasing an additional 1,229 shares during the last quarter. LeJeune Puetz Investment Counsel LLC lifted its position in DBV TECHNOLOGIE/S by 11.4% during the third quarter. LeJeune Puetz Investment Counsel LLC now owns 14,650 shares of the company’s stock valued at $126,000 after purchasing an additional 1,500 shares during the last quarter. Parametric Portfolio Associates LLC grew its stake in DBV TECHNOLOGIE/S by 27.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 66,958 shares of the company’s stock worth $550,000 after buying an additional 14,454 shares in the last quarter. BlackRock Inc. grew its stake in DBV TECHNOLOGIE/S by 7.7% in the 2nd quarter. BlackRock Inc. now owns 301,898 shares of the company’s stock worth $2,482,000 after buying an additional 21,561 shares in the last quarter. Finally, Bluefin Trading LLC purchased a new position in DBV TECHNOLOGIE/S in the 3rd quarter worth approximately $215,000. Institutional investors own 32.91% of the company’s stock.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: Are analyst ratings accurate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.